Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Arthur

Showing results (431-440 of 440) with videos related to

Pageof 44
Sort By:
You have reached the last page of results.This site can display upto 440 results.
Iscience|February 24, 2022
Nrf2 activation reprograms macrophage intermediary metabolism and suppresses the type I interferon responseDylan G Ryan, Elena V Knatko, Alva M Casey, et al.
Blood|October 24, 2002
Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)John C Byrd, Krzysztof Mrózek, Richard K Dodge, et al.
Nature|May 31, 2013
RAS-MAPK-MSK1 pathway modulates ataxin 1 protein levels and toxicity in SCA1Jeehye Park, Ismael Al-Ramahi, Qiumin Tan, et al.
Health Education Research|March 7, 2026
Codesigning COVID-19 booster promotion materials in online workshops with long-term care staff: a process evaluationKimberly C Arthur, Kanetha B Wilson, Breana Berry, et al.
Immunity|November 6, 2012
The short isoform of the CEACAM1 receptor in intestinal T cells regulates mucosal immunity and homeostasis via Tfh cell inductionLanfen Chen, Zhangguo Chen, Kristi Baker, et al.
The Lancet. Oncology|January 4, 2015
Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trialMohammed Z H Farooqui, Janet Valdez, Sabrina Martyr, et al.
Leukemia|April 18, 2002
Prognostic variables in newly diagnosed children and adolescents with acute myeloid leukemia: Children's Cancer Group Study 213R J Wells, D C Arthur, A Srivastava, et al.
Blood|November 15, 2013
GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunityMichael A Spinner, Lauren A Sanchez, Amy P Hsu, et al.
Nature Biotechnology|September 25, 2023
Killing tumor-associated bacteria with a liposomal antibiotic generates neoantigens that induce anti-tumor immune responsesMenglin Wang, Benoit Rousseau, Kunyu Qiu, et al.
JAMA Oncology|July 17, 2015
Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple MyelomaNeha Korde, Mark Roschewski, Adriana Zingone, et al.
Pageof 44

Showing results (431-440 of 440) with videos related to

Sort By:
Pageof 44
You have reached the last page of results.This site can display upto 440 results.
Iscience|February 24, 2022
Nrf2 activation reprograms macrophage intermediary metabolism and suppresses the type I interferon responseDylan G Ryan, Elena V Knatko, Alva M Casey, et al.
Blood|October 24, 2002
Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)John C Byrd, Krzysztof Mrózek, Richard K Dodge, et al.
Nature|May 31, 2013
RAS-MAPK-MSK1 pathway modulates ataxin 1 protein levels and toxicity in SCA1Jeehye Park, Ismael Al-Ramahi, Qiumin Tan, et al.
Health Education Research|March 7, 2026
Codesigning COVID-19 booster promotion materials in online workshops with long-term care staff: a process evaluationKimberly C Arthur, Kanetha B Wilson, Breana Berry, et al.
Immunity|November 6, 2012
The short isoform of the CEACAM1 receptor in intestinal T cells regulates mucosal immunity and homeostasis via Tfh cell inductionLanfen Chen, Zhangguo Chen, Kristi Baker, et al.
The Lancet. Oncology|January 4, 2015
Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trialMohammed Z H Farooqui, Janet Valdez, Sabrina Martyr, et al.
Leukemia|April 18, 2002
Prognostic variables in newly diagnosed children and adolescents with acute myeloid leukemia: Children's Cancer Group Study 213R J Wells, D C Arthur, A Srivastava, et al.
Blood|November 15, 2013
GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunityMichael A Spinner, Lauren A Sanchez, Amy P Hsu, et al.
Nature Biotechnology|September 25, 2023
Killing tumor-associated bacteria with a liposomal antibiotic generates neoantigens that induce anti-tumor immune responsesMenglin Wang, Benoit Rousseau, Kunyu Qiu, et al.
JAMA Oncology|July 17, 2015
Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple MyelomaNeha Korde, Mark Roschewski, Adriana Zingone, et al.
Pageof 44